Do Quality-Adjusted Life Years Discriminate Against the Elderly? An Empirical Analysis of Published Cost-Effectiveness Analyses

被引:4
|
作者
Xie, Feng [1 ,2 ,5 ]
Zhou, Ting [1 ,3 ]
Humphries, Brittany [1 ]
Neumann, Peter J. [4 ]
机构
[1] McMaster Univ, Fac Hlth Sci, Dept Hlth Res Methods Evidence & Impact, Hamilton, ON, Canada
[2] McMaster Univ, Fac Hlth Sci, Ctr Hlth Econ & Policy Anal, Hamilton, ON, Canada
[3] China Pharmaceut Univ, Ctr Pharmacoecon & Outcome Res, Nanjing, Peoples R China
[4] Tufts Med Ctr, Inst Clin Res & Hlth Policy Studies, Ctr Evaluat Value & Risk Hlth, Boston, MA USA
[5] McMaster Univ, Dept Hlth Res Methods Evidence & Impact, 1280 Main St West, Hamilton, ON L8S 4L8, Canada
关键词
age; cost-effectiveness analysis; elderly; discrimination; quality-adjusted life-year;
D O I
10.1016/j.jval.2024.03.011
中图分类号
F [经济];
学科分类号
02 ;
摘要
Objectives: Critics of quality-adjusted life-years argue that it discriminates against older individuals. However, little empirical evidence has been produced to inform this debate. This study aimed to compare published cost-effectiveness analyses (CEAs) on patients aged >= 65 years and those aged <65 years. Methods: We used the Tufts Cost-Effectiveness Analysis Registry to identify CEAs published in MEDLINE between 1976 and 2021. Eligible CEAs were categorized according to age (>= 65 years vs <65 years). The distributions of incremental cost-effectiveness ratios (ICERs) were compared between the age groups. We used logistic regression to assess the association between age groups and the cost-effectiveness conclusion adjusted for confounding factors. We conducted sensitivity analyses to explore the impact of mixed age and age-unknown groups and all ICERs from the same CEAs. Subgroup analyses were also conducted. Results: A total of 4445 CEAs categorized according to age <65 years (n = 3784) and age >= 65 years (n = 661) were included in the primary analysis. The distributions of ICERs and the likelihood of concluding that the intervention was cost-effective were similar between the 2 age groups. Adjusted odds ratios ranged from 1.132 (95% CI 0.930-1.377) to 1.248 (95% CI 0.970-1.606) (odds ratio >1 indicating that CEAs for age >= 65 years were more likely to conclude the intervention was cost-effective than those for age <65 years). Sensitivity and subgroup analyses found similar results. Conclusion: Our analysis found no systematic differences in published ICERs using quality-adjusted life-years between CEAs for individuals aged >= 65 years and those for individuals aged <65 years.
引用
收藏
页码:706 / 712
页数:7
相关论文
共 50 条
  • [21] Assessing the need for quality-adjusted cost-effectiveness studies of nanotechnological cancer therapies
    Bosetti, Rita
    Marneffe, Wim
    Vereeck, Lode
    NANOMEDICINE, 2013, 8 (03) : 487 - 497
  • [22] Adjunct entacapone to levodopa treatment in Parkinson's disease offers more quality-adjusted life years and reduces direct costs: A cost-effectiveness analysis
    Marttila, RJ
    Linna, M
    Taimela, E
    Takala, A
    NEUROLOGY, 2001, 56 (08) : A344 - A344
  • [23] Calculating and presenting disability adjusted life years (DALYs) in cost-effectiveness analysis
    Rushby, JF
    Hanson, K
    HEALTH POLICY AND PLANNING, 2001, 16 (03) : 326 - 331
  • [24] How are quality-adjusted life years defined in German studies? A systematic review of cost-utility analyses
    Schwappach, D. L. B.
    Boluarte, T. A.
    DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT, 2006, 131 (37) : 2004 - 2009
  • [25] RANKING COUNTRIES BY QUALITY-ADJUSTED LIFE EXPECTANCY, MEDICAL EXPENDITURES, AND COST EFFECTIVENESS
    Ghushchyan, V
    Chobanyan, A.
    Sullivan, P. W.
    VALUE IN HEALTH, 2016, 19 (03) : A282 - A282
  • [26] EFFECTIVENESS OF SUPERFICIAL VENOUS SURGERY IN TERMS OF QUALITY-ADJUSTED LIFE YEARS AND COSTS
    Eskelinen, E.
    Rasanen, P.
    Alback, A.
    Lepantalo, M.
    Eskelinen, A.
    Peltonen, M.
    Roine, R. P.
    SCANDINAVIAN JOURNAL OF SURGERY, 2009, 98 (04) : 229 - 233
  • [27] The cost-effectiveness of high-dose intravenous proton pump inhibition administered after endoscopic hemostasis using quality-adjusted life years as unit of effectiveness
    Barkun, Alan
    Adam, Viviane
    GASTROINTESTINAL ENDOSCOPY, 2008, 67 (05) : AB236 - AB236
  • [28] Does willingness to pay per quality-adjusted life year bring us closer to a useful decision rule for cost-effectiveness analysis?
    Polsky, D
    MEDICAL DECISION MAKING, 2005, 25 (06) : 605 - 606
  • [29] Effectiveness of hip or knee replacement surgery in terms of quality-adjusted life years and costs
    Rasanen, Pirjo
    Paavolainen, Pekka
    Sintonen, Hard
    Koivisto, Anna-Maija
    Marja, B.
    Ryynanen, Olli-Pekka
    Roine, Risto P.
    ACTA ORTHOPAEDICA, 2007, 78 (01) : 108 - 115
  • [30] Economic Evaluation of Coronary Artery Bypass Grafting Surgery With and Without Cardiopulmonary Bypass: Cost-Effectiveness and Quality-Adjusted Life Years in a Randomized Controlled Trial
    Al-Ruzzeh, Sharif
    Epstein, David
    George, Shane
    Bustami, Mahmoud
    Wray, Jo
    Ilsley, Charles
    Sculpher, Mark
    Amrani, Mohamed
    ARTIFICIAL ORGANS, 2008, 32 (11) : 891 - 897